New York: ConforMIS (NASDAQ:CFMS) Stock Has Just Had Its Buy Rating Reiterated by Canaccord Genuity. Shares now Have a $26.0 Target


ConforMIS (NASDAQ:CFMS) Rating Reaffirmed

Investment analysts at Canaccord Genuity now has a $26.0 price target on ConforMIS (NASDAQ:CFMS). Canaccord Genuity and their recent price target means a potential upside of 21.84% from the company’s stock close price. The rating has been unveiled in a comprehensive report on Tuesday morning.

From a total of 5 analysts covering ConforMIS Inc (NASDAQ:CFMS) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $26 while the lowest target price is $23. The mean of all analyst targets is $25.2 with a 23.18% above today’s ($21.92) stock price. ConforMIS Inc was the topic of 8 analyst reports since July 27, 2015 according to the firm StockzIntelligence Inc. Canaccord Genuity maintained shares on December 8 with “Buy” rating. Oppenheimer maintained CFMS stock in a recent report from August 12 with “Outperform” rating. Finally, JP Morgan initiated the stock with “Overweight” rating in a report issued on a July 27.

The stock increased 2.72% or $0.58 during the last trading session, striking $21.92. Approximately shares of stock traded hands. ConforMIS Inc (NASDAQ:CFMS) has risen 6.00% since November 9, 2015 and is uptrending. It has outperformed by 6.80% the S&P500.

New York: ConforMIS (NASDAQ:CFMS) Stock Has Just Had Its Buy Rating Reiterated by Canaccord Genuity. Shares now Have a $26.0 Target

ConforMIS, Inc. is a medical technology company. The company has a market cap of $868.80 million. The Firm uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, to fit each patient’s anatomy. It currently has negative earnings. It is engaged in offering a line of customized knee implants designed to restore the natural shape of a patient’s knee.

According to Zacks Investment Research, “ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company’s iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States.” Get a free copy of the Zacks research report on ConforMIS Inc (CFMS).